ATE531720T1 - Aza-benzofuranylverbindungen und anwendungsverfahren dafür - Google Patents
Aza-benzofuranylverbindungen und anwendungsverfahren dafürInfo
- Publication number
- ATE531720T1 ATE531720T1 AT07814272T AT07814272T ATE531720T1 AT E531720 T1 ATE531720 T1 AT E531720T1 AT 07814272 T AT07814272 T AT 07814272T AT 07814272 T AT07814272 T AT 07814272T AT E531720 T1 ATE531720 T1 AT E531720T1
- Authority
- AT
- Austria
- Prior art keywords
- aza
- methods
- benzofuranyl compounds
- benzofuranyl
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83916106P | 2006-08-21 | 2006-08-21 | |
| US87159106P | 2006-12-22 | 2006-12-22 | |
| US91762307P | 2007-05-11 | 2007-05-11 | |
| US94474107P | 2007-06-18 | 2007-06-18 | |
| PCT/US2007/076344 WO2008024725A1 (en) | 2006-08-21 | 2007-08-20 | Aza-benzofuranyl compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE531720T1 true ATE531720T1 (de) | 2011-11-15 |
Family
ID=38925647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07814272T ATE531720T1 (de) | 2006-08-21 | 2007-08-20 | Aza-benzofuranylverbindungen und anwendungsverfahren dafür |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080085886A1 (de) |
| EP (1) | EP2069354B1 (de) |
| JP (1) | JP5448818B2 (de) |
| KR (1) | KR101428116B1 (de) |
| AR (1) | AR062468A1 (de) |
| AT (1) | ATE531720T1 (de) |
| AU (1) | AU2007286808B2 (de) |
| BR (1) | BRPI0714635A2 (de) |
| CA (1) | CA2660546A1 (de) |
| ES (1) | ES2376771T3 (de) |
| IL (1) | IL196956A (de) |
| MX (1) | MX2009001878A (de) |
| NO (1) | NO20091197L (de) |
| PE (1) | PE20080611A1 (de) |
| TW (1) | TWI411614B (de) |
| WO (1) | WO2008024725A1 (de) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008024724A1 (en) * | 2006-08-21 | 2008-02-28 | Genentech, Inc. | Aza-benzothiophenyl compounds and methods of use |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| EP2085390A1 (de) * | 2008-01-31 | 2009-08-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Markierte Analoge von Halobenzamiden als multimodale Radiopharmazeutika und ihre Vorläufer |
| EP2370568B1 (de) | 2008-12-10 | 2017-07-19 | Dana-Farber Cancer Institute, Inc. | Mek mutanten mit resistenz gegen mek inhibitoren |
| AU2010237801A1 (en) | 2009-04-14 | 2011-10-20 | Syngenta Participations Ag | Haloalkylsulfonanilide derivative |
| CN102134218A (zh) * | 2009-06-15 | 2011-07-27 | 凯美隆(北京)药业技术有限公司 | 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂 |
| CA2789696C (en) | 2010-02-25 | 2017-11-07 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
| EP2545187B1 (de) | 2010-03-09 | 2018-09-05 | Dana-Farber Cancer Institute, Inc. | Verfahren zur diagnose und behandlung von krebs bei patienten mit resistenz bzw. entwicklung einer resistenz gegenüber einer ersten krebstherapie |
| US20120157448A1 (en) | 2010-11-22 | 2012-06-21 | Adam Cook | Compounds for treating neurodegenerative diseases |
| UA113850C2 (xx) | 2011-05-27 | 2017-03-27 | Хіральний синтез n-{3,4-дифтор-2-$(2-фтор-4-йодфеніл)аміно]-6-метоксифеніл}-1-$2,3-дигідроксипропіл]циклопропансульфонамідів | |
| BR112014002353B1 (pt) * | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| WO2014071183A1 (en) | 2012-11-02 | 2014-05-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| PL3099717T3 (pl) | 2014-01-31 | 2019-10-31 | Novartis Ag | Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie |
| EA201691765A1 (ru) | 2014-03-14 | 2016-12-30 | Новартис Аг | Молекулы антител против lag-3 и их применения |
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| BR112017000672A2 (pt) | 2014-07-15 | 2017-11-14 | Genentech Inc | composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek |
| EP3191126B1 (de) | 2014-09-13 | 2020-05-13 | Novartis AG | Kombinationstherapien aus alk-hemmern |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| EP3233918A1 (de) | 2014-12-19 | 2017-10-25 | Novartis AG | Kombinationstherapien |
| EP3328418A1 (de) | 2015-07-29 | 2018-06-06 | Novartis AG | Kombinationstherapien mit antikörpermolekülen gegen pd-1 |
| US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| US20180340025A1 (en) | 2015-07-29 | 2018-11-29 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| PT3370768T (pt) | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| CN106883270B (zh) | 2015-11-26 | 2019-03-26 | 财团法人工业技术研究院 | 有机金属化合物、包含其的有机发光装置 |
| CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| AU2017249229A1 (en) | 2016-04-15 | 2018-10-04 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| JP7212956B2 (ja) | 2017-05-19 | 2023-01-26 | エヌフレクション セラピューティクス インコーポレイテッド | 皮膚障害の処置用のピロロピリジン－アニリン化合物 |
| ES2913213T3 (es) * | 2017-05-19 | 2022-06-01 | Nflection Therapeutics Inc | Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos |
| KR102811888B1 (ko) | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
| MX2020004756A (es) | 2017-11-16 | 2020-08-20 | Novartis Ag | Terapias de combinacion. |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| US20210008047A1 (en) | 2018-02-13 | 2021-01-14 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| MX2020012598A (es) | 2018-05-24 | 2021-05-27 | Janssen Biotech Inc | Agentes aglutinantes del psma y usos de estos. |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| WO2020106305A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Thienyl-aniline compounds for treatment of dermal disorders |
| EP3883552B1 (de) | 2018-11-20 | 2025-04-09 | NFlection Therapeutics, Inc. | Cyanoaryl-anilin-verbindungen zur behandlung von hauterkrankungen |
| CN113473986B (zh) | 2018-11-20 | 2024-10-11 | 恩福莱克逊治疗有限公司 | 用于治疗皮肤疾病萘啶酮苯胺化合物 |
| AU2019402189B2 (en) | 2018-12-20 | 2023-04-13 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP3924054B1 (de) | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5- (piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dionderivate und ihre verwendungen |
| CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| AR118720A1 (es) | 2019-04-19 | 2021-10-27 | Janssen Biotech Inc | Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3 |
| US20230057071A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
| EP4168007A1 (de) | 2020-06-23 | 2023-04-26 | Novartis AG | Dosierschema mit 3-(1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivaten |
| CN117157065A (zh) | 2021-01-21 | 2023-12-01 | 恩福莱克逊治疗有限公司 | 吡咯并吡啶-苯胺化合物的晶型 |
| MX2023008909A (es) | 2021-01-28 | 2023-10-23 | Janssen Biotech Inc | Proteínas de unión a psma y usos de estas. |
| JP2024505562A (ja) | 2021-02-02 | 2024-02-06 | レス ラボラトイレス セルビエル | 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法 |
| EP4308935A1 (de) | 2021-03-18 | 2024-01-24 | Novartis AG | Biomarker für krebs und verfahren zur verwendung davon |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| EP4525925A1 (de) | 2022-05-20 | 2025-03-26 | Novartis AG | Epha2 bcl-xl-inhibitor-antikörper-wirkstoff-konjugate und verfahren zur verwendung davon |
| CN119562832A (zh) | 2022-05-20 | 2025-03-04 | 诺华股份有限公司 | Met bcl-xl抑制剂抗体-药物缀合物及其使用方法 |
| US20260048075A1 (en) | 2022-08-10 | 2026-02-19 | Vib Vzw | Inhibition of TCF4/ITF2 in the Treatment of Cancer |
| EP4676540A1 (de) | 2023-03-10 | 2026-01-14 | Novartis AG | Panras-inhibitor-antikörper-wirkstoff-konjugate und verfahren zur verwendung davon |
| UY40985A (es) | 2023-11-22 | 2025-06-30 | Servier Lab | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos |
| WO2025215536A1 (en) | 2024-04-10 | 2025-10-16 | Novartis Ag | Macrocyclic panras inhibitors for the treatment of cancer |
| WO2026019990A1 (en) | 2024-07-18 | 2026-01-22 | Genentech, Inc. | Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies |
| CN119285968B (zh) * | 2024-09-19 | 2025-06-20 | 黑龙江大学 | 一种光致变色稀土聚合物及其制备方法和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5328920A (en) * | 1991-04-17 | 1994-07-12 | Hoechst-Roussel Pharmaceuticals Incorporated | Substituted (pyridinylamino)-indoles |
| US5214204A (en) * | 1991-07-19 | 1993-05-25 | Abbott Laboratories | Arylamidoalkyl-n-hydroxyurea compounds having lipoxygenase inhibitory activity |
| EP0530537B1 (de) * | 1991-08-12 | 1997-01-08 | Takeda Chemical Industries, Ltd. | Kondensierte Pyrimidinderivate, ihre Herstellung und ihre Verwendung als Antitumormittel |
| EP0545478A1 (de) * | 1991-12-03 | 1993-06-09 | MERCK SHARP & DOHME LTD. | Heterocyclische Verbindungen als Tachykininantagoniste |
| JPH05345780A (ja) * | 1991-12-24 | 1993-12-27 | Kumiai Chem Ind Co Ltd | ピリミジンまたはトリアジン誘導体及び除草剤 |
| US5852046A (en) * | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
| US5350748A (en) * | 1993-08-18 | 1994-09-27 | Warner-Lambert Company | 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion |
| DE4425609A1 (de) * | 1994-07-20 | 1996-01-25 | Bayer Ag | Benzofuranyl- und Benzothienyloxazolidinone |
| FR2777886B1 (fr) * | 1998-04-27 | 2002-05-31 | Adir | Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6410562B1 (en) * | 1998-12-18 | 2002-06-25 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
| ID30439A (id) * | 1999-01-13 | 2001-12-06 | Warner Lambert Co | Benzoheterosiklus dan penggunaannya sebagai penghambat mek |
| JP2000204079A (ja) * | 1999-01-13 | 2000-07-25 | Warner Lambert Co | ジアリ―ルアミン |
| FR2799756B1 (fr) * | 1999-10-15 | 2001-12-14 | Adir | Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AU7349801A (en) * | 2000-07-19 | 2002-01-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| DE10110750A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| US6653346B1 (en) * | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
| SG2013013339A (en) * | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| WO2003077855A2 (en) * | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US20040009976A1 (en) * | 2002-04-30 | 2004-01-15 | Kumiko Takeuchi | Hypoglycemic imidazoline compounds |
| CL2003002287A1 (es) * | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| JP2005104838A (ja) * | 2003-01-09 | 2005-04-21 | Tanabe Seiyaku Co Ltd | 縮合フラン化合物 |
| US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| DE10351436A1 (de) * | 2003-11-04 | 2005-06-09 | Merck Patent Gmbh | Verwendung von Thienopyrimidinen |
| CN101061101B (zh) * | 2003-12-22 | 2011-09-07 | 巴斯利尔药物股份公司 | 芳酰基呋喃和芳酰基噻吩 |
| BRPI0608659A2 (pt) * | 2005-04-06 | 2010-11-30 | Astrazeneca Ab | composto, métodos para limitar a proliferação celular, de tratamento de um ser humano ou animal sofrendo de uma doença, e de tratamento de profilaxia do cáncer, para tratar cáncer, de tratamento de infecções associadas com cáncer, e de profilaxia de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir chk1 cinase, e um pak cinase, e para limitar a tumorigênese em um ser humano ou animal, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo |
| AU2006284751A1 (en) * | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| WO2008024724A1 (en) * | 2006-08-21 | 2008-02-28 | Genentech, Inc. | Aza-benzothiophenyl compounds and methods of use |
| TWI389895B (zh) * | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法 |
| WO2008036196A2 (en) * | 2006-09-21 | 2008-03-27 | Wyeth | Indolylalkylpyridin-2-amines for the inhibition of beta-secretase |
-
2007
- 2007-08-20 CA CA002660546A patent/CA2660546A1/en not_active Abandoned
- 2007-08-20 MX MX2009001878A patent/MX2009001878A/es active IP Right Grant
- 2007-08-20 EP EP07814272A patent/EP2069354B1/de active Active
- 2007-08-20 WO PCT/US2007/076344 patent/WO2008024725A1/en not_active Ceased
- 2007-08-20 KR KR1020097005786A patent/KR101428116B1/ko not_active Expired - Fee Related
- 2007-08-20 US US11/894,506 patent/US20080085886A1/en not_active Abandoned
- 2007-08-20 BR BRPI0714635-3A patent/BRPI0714635A2/pt not_active IP Right Cessation
- 2007-08-20 AU AU2007286808A patent/AU2007286808B2/en not_active Ceased
- 2007-08-20 ES ES07814272T patent/ES2376771T3/es active Active
- 2007-08-20 AT AT07814272T patent/ATE531720T1/de active
- 2007-08-20 JP JP2009525720A patent/JP5448818B2/ja not_active Expired - Fee Related
- 2007-08-21 PE PE2007001135A patent/PE20080611A1/es not_active Application Discontinuation
- 2007-08-21 TW TW096130982A patent/TWI411614B/zh not_active IP Right Cessation
- 2007-08-21 AR ARP070103712A patent/AR062468A1/es unknown
-
2009
- 2009-02-09 IL IL196956A patent/IL196956A/en not_active IP Right Cessation
- 2009-03-20 NO NO20091197A patent/NO20091197L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2376771T3 (es) | 2012-03-16 |
| KR101428116B1 (ko) | 2014-08-07 |
| NO20091197L (no) | 2009-05-20 |
| MX2009001878A (es) | 2009-03-03 |
| AR062468A1 (es) | 2008-11-12 |
| EP2069354B1 (de) | 2011-11-02 |
| TW200817415A (en) | 2008-04-16 |
| CA2660546A1 (en) | 2008-02-28 |
| IL196956A (en) | 2014-04-30 |
| JP5448818B2 (ja) | 2014-03-19 |
| PE20080611A1 (es) | 2008-07-21 |
| JP2010501585A (ja) | 2010-01-21 |
| EP2069354A1 (de) | 2009-06-17 |
| BRPI0714635A2 (pt) | 2013-06-18 |
| IL196956A0 (en) | 2009-11-18 |
| TWI411614B (zh) | 2013-10-11 |
| AU2007286808B2 (en) | 2012-12-06 |
| AU2007286808A1 (en) | 2008-02-28 |
| WO2008024725A1 (en) | 2008-02-28 |
| KR20090042332A (ko) | 2009-04-29 |
| US20080085886A1 (en) | 2008-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2019010I2 (el) | Νεες ενωσεις και συνθεσεις και μεθοδοι χρησης | |
| HUS2100009I1 (hu) | Halauxifen-metil és piroxszulam kombinációja | |
| ATE511509T1 (de) | Azaindolylverbindungen und anwendungsverfahren | |
| CY2020021I2 (el) | Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης | |
| EP2079544A4 (de) | Arsenabsorbierende zusammensetzung und verwendungsverfahren | |
| IL196956A0 (en) | Aza-benzofuranyl compounds and methods of use | |
| IL197060A0 (en) | Aza-benzothiophenyl compounds and methods of use | |
| PL2152256T3 (pl) | Związki aktywujące telomerazę i sposoby ich zastosowania | |
| IL198397A0 (en) | Anilinopiperazine derivatives and methods of use thereof | |
| DE602007010272D1 (de) | Parkhilfevorrichtung und parkhilfeverfahren | |
| EP2122054A4 (de) | Vliestafel und konstruktionsverfahren dafür | |
| CR10815A (es) | Nuevos derivados de isoquinolina e isoquinolinona sustituidos | |
| DK1940839T3 (da) | Pyridopyrimidione Inhibitors of P13Ka | |
| ATE526567T1 (de) | Zusammensteller und zusammenstellungsverfahren | |
| EP1845849A4 (de) | Exoskelett für die beine | |
| EP1874239A4 (de) | Halb angetriebenes exoskelett der unteren extremität | |
| IL194028A0 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
| BRPI0909954A2 (pt) | "diazacarbazóis e métodos de uso" | |
| HRP20141261T1 (xx) | Spojevi tioninija i njihove uporabe | |
| EP2066174A4 (de) | Zusammensetzungen mit alpha-1-antitrypsin und verwendungsverfahren dafür | |
| DK2069467T3 (da) | Adskillende sammensætninger og fremgangsmåder til anvendelse | |
| IL185309A0 (en) | Isoqunoline compounds and methods of use thereof | |
| IL202740A0 (en) | Quinazolinone compounds and methods of use thereof | |
| DK2081955T3 (da) | Metastinderivater og anvendelse deraf | |
| EP2139325A4 (de) | Anti-angiogenese-mittel und anwendungsverfahren dafür |